Reslizumab
Reslizumab (pronunciation: rez-LIZ-oo-mab) is a monoclonal antibody designed for the treatment of asthma and other immune system disorders. It is marketed under the brand name Cinqair by Teva Pharmaceuticals.
Etymology
The name "Reslizumab" is derived from the International Nonproprietary Names (INN) system, which is used to name pharmaceutical substances. The "-mab" suffix indicates that it is a monoclonal antibody, a type of protein made in the lab that can bind to substances in the body.
Usage
Reslizumab is used to treat severe asthma in patients who have a high level of a certain white blood cell (eosinophils). It helps to decrease the number of asthma attacks in these patients. Reslizumab is not used to relieve sudden breathing problems and will not replace a rescue inhaler.
Mechanism of Action
Reslizumab works by reducing the number of eosinophils, a type of white blood cell that contributes to asthma symptoms. It does this by binding to the protein interleukin 5 (IL-5), which plays a key role in the life cycle of eosinophils.
Related Terms
See Also
External links
- Medical encyclopedia article on Reslizumab
- Wikipedia's article - Reslizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski